During an in-person Community Case Forum event, Ticiana Leal, MD, discussed the trials of lurbinectedin and tarlatalamb as therapy for previously treated small cell lung cancer.
August II, 2024
In an interview with Peers & Perspectives in Oncology, Thomas “Greg” Knight, MD, discusses how Levine Cancer set up its Financial Toxicity Tumor Board to get the lead decision makers on the same page for patients and the importance of having this resource at all cancer centers.
During a Case-Based Roundtable® event, Pierre Gholam moderated a discussion on how to proceed with a patient presenting with a LI-RADS 5 mass suspected of being hepatocellular carcinoma.
During a Case-Based Roundtable® event, Rafat Abonour, MD, moderated a peer discussion on the use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma.
During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, discussed dose modification approaches for patients receiving combination immunotherapy/tyrosine kinase inhibitor therapy for advanced renal cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
2
Considering Immunotherapy Rechallenge and TILs for Recurrent Mucosal Melanoma
3
B7-H3–Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
4
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Tumors
5